Doximity, Inc. (NASDAQ:DOCS) Director Sells $25,820.94 in Stock

Doximity, Inc. (NASDAQ:DOCS) Director Watkin Phoebe L. Yang sold 1,011 shares of Doximity stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $25.54, for a total transaction of $25,820.94. Following the completion of the transaction, the director now owns 11,258 shares of the company’s stock, valued at approximately $287,529.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Doximity Stock Up 0.7 %

Shares of NASDAQ DOCS opened at $25.67 on Friday. The firm’s fifty day moving average is $27.84 and its 200 day moving average is $27.32. The company has a market cap of $4.76 billion, a price-to-earnings ratio of 35.65, a PEG ratio of 5.12 and a beta of 1.22. Doximity, Inc. has a 52 week low of $19.71 and a 52 week high of $31.86.

Doximity (NASDAQ:DOCS) last announced its quarterly earnings data on Thursday, May 16th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.04. Doximity had a return on equity of 17.44% and a net margin of 31.04%. The business had revenue of $118.06 million during the quarter, compared to analysts’ expectations of $116.46 million. Equities research analysts anticipate that Doximity, Inc. will post 0.74 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on DOCS. Needham & Company LLC reiterated a “hold” rating on shares of Doximity in a research note on Friday, May 17th. Morgan Stanley restated an “underweight” rating and set a $25.00 price objective on shares of Doximity in a research report on Tuesday, April 23rd. JPMorgan Chase & Co. raised shares of Doximity from an “underweight” rating to a “neutral” rating and set a $25.00 price target on the stock in a research report on Thursday, April 25th. William Blair reissued an “outperform” rating on shares of Doximity in a report on Friday, May 17th. Finally, Evercore ISI upped their target price on Doximity from $28.00 to $29.00 and gave the stock an “in-line” rating in a research note on Friday, May 17th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $28.00.

Institutional Trading of Doximity

Several institutional investors and hedge funds have recently modified their holdings of DOCS. LRI Investments LLC bought a new stake in Doximity in the first quarter worth $27,000. First Horizon Advisors Inc. grew its stake in Doximity by 111.3% in the fourth quarter. First Horizon Advisors Inc. now owns 995 shares of the company’s stock worth $28,000 after purchasing an additional 524 shares in the last quarter. Blue Trust Inc. increased its stake in shares of Doximity by 621.4% during the second quarter. Blue Trust Inc. now owns 1,385 shares of the company’s stock valued at $37,000 after buying an additional 1,193 shares during the period. GAMMA Investing LLC purchased a new stake in shares of Doximity in the 4th quarter worth approximately $40,000. Finally, DekaBank Deutsche Girozentrale purchased a new stake in Doximity during the first quarter worth $46,000. 87.19% of the stock is currently owned by institutional investors.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.